SCHEMBL1377485

SCHEMBL1377485

CC1CCCN(C(=O)c2ccc3cc(OC4CCN(C(C)C)C4)ccc3n2)C1

nearest known ligand 0.75

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 15/20 0.75
SCN9A Q15858 4/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380892 0.95 HRH3 (0.82) HRH3SCN9A
SCHEMBL1377358 0.92 HRH3 (0.89) HRH3SCN9A
SCHEMBL1379507 0.90 HRH3 (0.76) HRH3SCN9A
SCHEMBL1380440 0.87 HRH3 (0.74) HRH3SCN9A
SCHEMBL1379417 0.86 HRH3 (0.69) HRH3SCN9A
SCHEMBL1381783 0.86 HRH3 (0.89) HRH3SCN9A
SCHEMBL1377924 0.86 HRH3 (1.00) HRH3SCN9A
SCHEMBL1378728 0.86 HRH3 (0.96) HRH3SCN9A
SCHEMBL2209035 0.85 HRH3 (0.68) HRH3
SCHEMBL2245117 0.85 HRH3 (0.80) HRH3SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805166-B1 QUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-27 EP claimed
JP-4660553-B2 2011-03-30 JP claimed
US-7534891-B2 Quinoline derivatives as H3R inverse agonists HOFFMAN-LA ROCHE INC. (US) 2009-05-19 US claimed
JP-2008517003-A 2008-05-22 JP claimed
EP-1805166-A1 QUINOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-07-11 EP claimed
WO-2006045416-A1 QUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-04 WO claimed
US-20060084679-A1 Quinoline derivatives as H3R inverse agonists HOFFMANN-LA ROCHE INC. 2006-04-20 US claimed
EP-1805166-B1 QUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-27 EP disclosed
US-7534891-B2 Quinoline derivatives as H3R inverse agonists HOFFMAN-LA ROCHE INC. (US) 2009-05-19 US disclosed
EP-1805166-A1 QUINOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-07-11 EP disclosed
WO-2006045416-A1 QUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-04 WO disclosed
US-20060084679-A1 Quinoline derivatives as H3R inverse agonists HOFFMANN-LA ROCHE INC. 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084679-A1 Quinoline derivatives as H3R inverse agonists HRH3, HRH4, HRH1 HRH3 1/4885SCN9A 690/4885NPC1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.